The Union Ministry of Health has proposed sweeping amendments to the Medical Devices Rules, 2017, aiming to significantly compress timelines for licensing and auditing of medical devices in India. The move is designed to accelerate device availability while maintaining quality standards, with stakeholder comments invited over 30 days.
Key Timeline Reductions for Class B Devices
The amendments propose six changes targeting specific stages of the licensing and quality audit process. For Class B devices—low-to-moderate risk, non-invasive or minimally invasive equipment such as hypodermic needles, surgical gloves, and blood pressure monitors—the scrutiny period for applications has been reduced to 30 days. Under the proposed amendment to Rule 20, Sub-rule (5), the State Licensing Authority must complete scrutiny and assign applications to notified bodies within 30 days of submission. A new sub-clause 5(A) mandates that the manufacturing site conform to Quality Management System (QMS) requirements, verified through an audit by a notified body before any licence is granted. A 30-day deadline has been introduced for the site audit. A further sub-clause (i)(a) addresses quality non-conformance found during audit, requiring compliance verification within 20 days of receipt of the manufacturer's compliance report.
Changes for High-Risk Class C and D Devices
Another amendment to Rule 21, Sub-rule (4), which governs applications for manufacturing Class C or Class D devices, reduces the procedural timeline for scrutiny of papers from 45 days to 30 days. Class C and D devices are high-risk, moderate-to-life-supporting equipment regulated by the central drug authority. These include invasive devices used for administering life-sustaining substances or involving energy transfer, such as dialysis machines, pacemakers, and coronary stents.
Steepest Cut: Licence Grant Timeline Halved
An amendment to Rule 23, Sub-rule (1), which deals with granting a licence to manufacture for sale or distribution of Class C or D devices, reduces the site inspection timeline from 60 days to 55 days. The most significant compression appears in Rule 25, Sub-rule (1), where the deadline for granting a licence or loan licence after receiving the inspection team's report is proposed to be reduced from 45 days to 20 days—a reduction of over 55%.
Background and Impact
The Medical Devices Rules were published on January 31, 2017, to create a comprehensive regulatory framework covering manufacture, import, sale, and distribution of medical devices in India, including surgical instruments, diagnostic equipment, implants, and in-vitro diagnostic kits. The proposed amendments directly address time taken at various licensing stages—from initial application scrutiny and assignment to notified bodies through site audit and compliance verification to final licensing. The sharp reduction in timelines, particularly the halving of the Rule 25 deadline, aims to make India's medical device regulatory process more competitive globally, where long approval timelines have been cited as a deterrent by manufacturers and investors. Parallel insertion of quality conformance requirements at each stage, including mandatory QMS audit and structured compliance verification windows, indicates that speed improvements are designed to accompany, not replace, quality rigour.
